title: [Pharmacological and clinical profile of solifenacin succinate (Vesicare) developed as a new therapeutic agent for overactive bladder].
authors.affiliation: akiyoshi.ohtake@jp.astellas.com
authors.forename: Akiyoshi
authors.initials: A
authors.lastname: Ohtake
authors.forename: Shuichi
authors.initials: S
authors.lastname: Sato
authors.forename: Ken
authors.initials: K
authors.lastname: Ikeda
authors.forename: Masao
authors.initials: M
authors.lastname: Sasamata
authors.forename: Keiji
authors.initials: K
authors.lastname: Miyata
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D018727:Muscarinic Antagonists / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D009130:Muscle, Smooth / Q000187:drug effects; D011812:Quinuclidines / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D011976:Receptors, Muscarinic / Q000378:metabolism; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D001743:Urinary Bladder / Q000187:drug effects; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000503:physiopathology; D014554:Urination / Q000187:drug effects
chemical_list: D018727:Muscarinic Antagonists; D011812:Quinuclidines; D011976:Receptors, Muscarinic; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate